Managing anticoagulation in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) is a complex clinical challenge. In this episode, we explore the delicate balance between preventing venous thromboembolism (VTE) and minimizing bleeding risks in this vulnerable population. We discuss the evolving role of direct oral anticoagulants (DOACs), including the limited and often controversial evidence supporting their use in ESRD, alongside the continued relevance of warfarin. Drawing on guideline recommendations, observational studies, and emerging research on novel agents such as Factor XI inhibitors, we highlight the nuances of decision-making and the importance of individualized therapy. Whether you’re a clinician, researcher, or learner, this episode provides a concise yet comprehensive look at where the field stands and where it’s headed.

What if treating diabetic ketoacidosis didn’t always require IV drips, ICU beds, or long hospital stays? In this episode, we explore the SQuID protocol, a cutting-edge approach that uses subcutaneous insulin for mild to moderate DKA. Evidence shows it can safely resolve DKA, speed up recovery, and free up critical hospital resources...all while keeping outcomes comparable to traditional treatment. We’ll also discuss the important limitations, safety considerations, and the steps needed before this approach can be widely adopted. Tune in to hear how SQuID could transform the way we manage DKA.

In this episode, we dive into the clinical nuances of using gabapentin and pregabalin for chronic neuropathic pain. Join us as we unpack the evolving approach to gabapentinoid prescribing, including key pharmacologic differences, practical dose limitations, and when to consider switching therapies. Learn why doses of gabapentin above 1800 mg/day may not provide added benefit...and how pregabalin’s consistent absorption and greater binding affinity might offer an effective alternative, even with cost considerations. Whether you're a clinician or simply curious about pain management, this episode brings evidence-based insights to the forefront.

In this episode, we explore how a targeted approach to neurotransmitters such as serotonin, dopamine, and acetylcholine, can optimize antiemetic therapy. We break down key safety concerns for commonly used agents, including QT prolongation with ondansetron, extrapyramidal effects from metoclopramide and phenothiazines, and anticholinergic risks with diphenhydramine. Tune in for practical tips to balance efficacy and safety in managing nausea and vomiting across clinical settings.

In today’s episode, we explore the updated approach to managing status epilepticus. We walk through a practical, stepwise treatment strategy starting with benzodiazepines, followed by ketamine, and then anti-epileptics like levetiracetam and lacosamide. We also cover recommended intubation and general anesthetic choices for refractory cases, emphasizing the importance of early airway management. Stay tuned to sharpen your emergency care skills and improve outcomes for patients facing seizures.

In this episode, we dive into the PREVENT CLOT trial, which compared aspirin to low-molecular-weight heparin (LMWH) for thromboprophylaxis in orthopedic trauma. While the study found aspirin to be noninferior in preventing all-cause mortality, some clinicians raise concerns about its limited generalizability. We break down the findings, the controversy, and what it all means for real-world practice, especially in higher-risk patients. Tune in for a balanced look at evidence-based prophylaxis and the importance of individualized care.

In this episode, we dive into the evolving practice of administering intravenous (IV) push antibiotics, a method gaining traction across emergency departments and outpatient antimicrobial programs. Prompted in part by IV fluid shortages during natural disasters, healthcare providers have increasingly embraced IV push for its speed, efficiency, and potential to reduce hospital stays. We explore what the evidence says about safety, cost savings, and patient outcomes, and discuss the clinical considerations that guide when and when not to use this approach. From resource-strapped EDs to home-based care, IV push antibiotics are reshaping antimicrobial delivery. But is faster always better? Tune in as we unpack the data and practical implications.

In this episode, we explore a groundbreaking case report introducing a novel approach to buprenorphine induction for patients with Opioid Use Disorder, especially those using fentanyl. Learn how low-dose intravenous naloxone is used to safely trigger moderate withdrawal, allowing for immediate buprenorphine initiation and dramatically shortening the induction timeline. Tune in to hear how this protocol could change the way we manage OUD in acute care settings.

This episode covers practical, evidence-informed strategies for reversing anticoagulant and antiplatelet medications in critical bleeding scenarios, including intracerebral hemorrhage. We review reversal protocols for warfarin, dabigatran, and Factor Xa inhibitors, and discuss the roles of PCC, FFP, DDAVP, and tranexamic acid. Key pitfalls in reversal therapy are examined, along with guidance on tailoring interventions to individual patients.

In this episode, we break down how to assess liver injury and understand its impact on drug therapy. We explore the difference between liver enzymes and true liver function tests, why normal labs can be misleading in cirrhosis, and how impaired hepatic metabolism affects drug efficacy and toxicity. Tune in for practical insights on adjusting medications safely in patients with liver dysfunction.

This episode takes a deep dive into the fundamentals of medication overdose management in hospital and critical care settings. We explore the four key pillars of treatment: supportive care, antidotes, decontamination, and enhanced elimination...highlighting why supportive care often makes the greatest impact. You’ll also learn key clinical pearls and considerations to guide decision-making and navigate the limited landscape of antidotes. A must-listen for pharmacists and healthcare professionals facing toxicologic emergencies on the front lines.

This episode highlights the vital role of emergency pharmacists during high-stakes resuscitations such as cardiac arrests and trauma codes. We explore how their involvement improves patient outcomes by reducing medication errors, ensuring accurate dosing, and contributing to rapid clinical decision-making. Backed by research, we also discuss the importance of targeted training programs that go beyond standard life support, equipping pharmacists with the skills and confidence needed to excel in these fast-paced, high-pressure environments. From managing crash carts to anticipating medication needs, emergency pharmacists are a critical, but often overlooked, part of the code team. As an emergency medicine pharmacist, this topic is deeply personal...I’ve seen how timely medication support and clinical decision-making can make a life-saving difference during high-stakes resuscitations. Tune in to learn how empowering pharmacists can make a life-saving difference!

When every second counts, speed matters. But how fast is too fast when it comes to giving intravenous antiseizure medications? In this episode, we dive into the latest research on rapid administration of lacosamide, levetiracetam, and valproate. From intravenous push to piggyback infusions, we break down what the data says about safety, side effects, and real-world efficiency. Join us as we explore how faster medication delivery could reshape emergency seizure care and what hospitals need to consider before making the switch.

https://academic.oup.com/ajhp/advance-article-abstract/doi/10.1093/ajhp/zxaf214/8237247?redirectedFrom=fulltext&login=false

In this episode, we dive into the complex issue of diuretic resistance in congestive heart failure (CHF), focusing especially on loop diuretics. We break down how these medications work, why they sometimes stop working, and the physiological mechanisms behind resistance including post-diuretic sodium retention, the braking phenomenon, and cardiorenal syndrome. You'll also hear about evidence-based strategies to overcome resistance, from dietary interventions and dosing adjustments to combination diuretic therapy. Whether you're a clinician or a curious learner, this episode will help you understand why diuretics fail...and what to do about it.

In this episode, we explore the role of levetiracetam (LEV) dosing in the management of benzodiazepine-refractory status epilepticus (BRSE), a life-threatening neurologic emergency. We review recent evidence comparing lower (<30 mg/kg) versus higher (≥30 mg/kg) weight-based LEV loading doses. The findings suggest that higher doses are more effective in terminating seizures and are linked to improved outcomes, including reduced need for intubation, ICU admission, and lower mortality. Join us as we discuss how these results may inform clinical decisions and optimize care in status epilepticus.

https://www.cambridge.org/core/journals/canadian-journal-of-neurological-sciences/article/evaluating-levetiracetam-weightbased-dosing-in-benzodiazepinerefractory-status-epilepticus/6F4AE79B03D3A38F0874CFDC4E5B74C5

In this episode, we examine phenobarbital monotherapy as an emerging approach to managing alcohol withdrawal syndrome. We discuss the advantages of phenobarbital over traditional benzodiazepine-based regimens, including more predictable pharmacokinetics, a wider therapeutic index, and broader neurological effects. Topics include accurate diagnosis, the benefits of phenobarbital’s long half-life for sustained symptom control and auto-tapering, and its potential to reduce intubation rates and complications. We also address contraindications and practical considerations for implementing a phenobarbital-first strategy in clinical practice.

In this episode, we explore ActionADE—a web-based application designed to prevent repeat adverse drug events (ADEs), a major cause of emergency room visits in Canada. We discuss how the platform improves communication across healthcare settings by standardizing ADE documentation and sharing it through connected electronic systems. Learn how pharmacists and clinicians are using ActionADE to make safer prescribing decisions, coordinate care, and protect patients from harmful re-exposures. Discover how this simple intervention is transforming medication safety and creating a more connected, collaborative healthcare system.

https://actionade.org/

In this episode, we explore evidence-based pharmacological treatments for severe gastrointestinal bleeding, drawing from Cochrane systematic reviews. Topics include the use of antibiotic prophylaxis in cirrhotic patients to prevent infections and reduce mortality, the impact of proton pump inhibitors (PPIs) started before endoscopy on patient outcomes, and the effectiveness of somatostatin analogues for managing acute bleeding from esophageal varices. Join us for a deep dive into strategies that improve care and outcomes in upper gastrointestinal hemorrhage.

In this episode, we focus on Advanced Trauma Life Support (ATLS) principles, with a special emphasis on the role of tranexamic acid (TXA) in trauma care. We review key clinical trials, including CRASH-2 and CRASH-3, discussing their findings, methodologies, and ongoing debates about TXA’s efficacy and safety in major trauma and traumatic brain injury. Additionally, we cover important trauma management topics such as the use of intravenous calcium during massive transfusions and the strategy of permissive hypotension.

In this episode, we explore hyponatremia, a common yet complex electrolyte disorder in hospitalized adults. We discuss causes, diagnostic approaches, and treatment strategies, including the DDAVP clamp-bolus technique for precise sodium correction. We also review recent evidence showing that more rapid correction of severe hyponatremia may be associated with reduced mortality and shorter hospital stays without significantly increasing the risk of osmotic demyelination syndrome (ODS). Additionally, we highlight important cautions around the use of vaptans and emphasize the need for careful monitoring and individualized care in managing this challenging condition.

In this episode, we explore the urgent management of convulsive status epilepticus, focusing on the efficacy and safety of anticonvulsant medications. We review first-line benzodiazepine therapy and examine second-line options—including fosphenytoin, phenytoin, levetiracetam, and valproate—with insights from the ESETT trial showing similar effectiveness among them. We also discuss the emerging role of ketamine for refractory cases, highlighting its unique mechanism and neuroprotective potential. Join us as we emphasize the importance of rapid, effective treatment to reduce neuronal injury and improve outcomes.

In this episode, we dive into the latest updates on medications used in Advanced Cardiovascular Life Support (ACLS), focusing on epinephrine, amiodarone, lidocaine, vasopressin, and esmolol. We also discuss the VSE protocol (vasopressin, steroids, and epinephrine), highlighting its potential to improve ROSC outcomes. Additionally, we review changes in timing, dosing, and clinical indications, along with post-cardiac arrest medication management strategies.

In this episode, we provide a thorough overview of Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS), two critical diabetic emergencies. Drawing from the EMCrit Project’s expert content, we cover key topics including diagnosis, pathophysiology, and practical management strategies such as fluid resuscitation, electrolyte replacement, and insulin therapy. We also address complex situations like euglycemic DKA, DKA in patients on hemodialysis, and considerations for intubation. Additionally, we highlight important differences between DKA and HHS and common treatment pitfalls to avoid.

Dive into the world of pharmacology as we explore how warfarin interacts with antibiotics at a molecular level. This episode highlights the crucial role of CYP2C9 metabolism in regulating S-warfarin and explains why certain antibiotics, like metronidazole and fluconazole, can significantly impact INR levels. We also unpack the challenge of separating true drug-drug interactions from infection-driven effects, giving you a clear look at the science behind these complex interactions. Perfect for pharmacists, clinicians, and anyone fascinated by how drugs work in the body.

In this episode, we dive into the latest evidence-based guidelines for managing sepsis and septic shock from the Surviving Sepsis Campaign 2021. Topics include fluid therapy, vasopressor use, and long-term patient outcomes. We also discuss insights from the EMCrit Project, an independent platform providing practical, cutting-edge perspectives on timely intervention in sepsis care, including a critical analysis of the fallacy of time-to-intervention studies and their impact on clinical practice.

In this episode, we explore an innovative approach to managing Parkinson’s symptoms in patients with swallowing difficulties. Hear the story of an 85-year-old man with Lewy body dementia who experienced rapid symptom relief through sublingual administration of crushed levodopa/carbidopa—a practical alternative when traditional oral or rectal routes aren’t feasible. We discuss the challenges of medication delivery in dysphagic patients, the potential benefits and limitations of sublingual dosing, and the need for further research to optimize this promising method.

This episode explores key aspects of managing cerebrovascular events, with a focus on intracranial hemorrhage (ICH) and ischemic stroke. We review clinical trials investigating optimal blood pressure targets in acute ICH, and discuss best practices for managing subarachnoid hemorrhage (SAH), including blood pressure control and seizure prophylaxis. Guidelines for reversing antithrombotic agents in various types of ICH are covered, along with a deep dive into the evidence behind alteplase use in acute ischemic stroke, including major trials like NINDS, ECASS-III, and IST-3—highlighting the evidence, controversies, and evolving practice considerations.

This episode provides a comprehensive overview of Rapid-Sequence Intubation (RSI), a vital procedure for securing a patient’s airway. It explores the pharmacology, pharmacokinetics, and safety of medications used in RSI, focusing on pretreatment, induction, and paralysis. Key sedative induction agents such as etomidate, ketamine, and propofol, along with neuromuscular blockers like succinylcholine and rocuronium, are discussed in terms of their benefits, contraindications, and side effects. The episode also highlights the critical role of the emergency department pharmacist in ensuring safe and effective RSI, including medication selection and managing challenges such as drug shortages.

Tranexamic acid (TXA) has been hailed as a game-changer in bleeding management...but does the evidence really support its widespread use? In this episode, we dive into the research behind TXA across multiple clinical settings: trauma, surgery, postpartum hemorrhage, GI bleeds, intracranial hemorrhage, and more. We explore landmark trials like CRASH-2 and CRASH-3, discuss why small positive studies don’t always translate into meaningful patient outcomes, and unpack the nuances of timing, context, and risk. Join us as we separate hype from evidence and ask the big question...where does TXA truly belong in emergency medicine?

In this episode, we dive into a groundbreaking exploratory analysis from the Annals of Emergency Medicine examining the PATCH-Trauma trial. Researchers investigated the optimal timing for administering tranexamic acid (TXA) to patients with severe trauma, challenging the long-standing 3-hour window established by the CRASH-2 trial. The findings are striking...giving TXA within 90 minutes of injury significantly reduces 28-day mortality, while administration after 120 minutes may offer no benefit... Join us as we explore how these results could reshape trauma care guidelines and highlight the critical role of time-sensitive interventions in saving lives.

Ali A, Gruen RL, Bernard SA, Burns B, Forbes AB, Gantner DC, McArthur CJ, Maegele M, Mitra B; PATCH-Trauma trial investigators. Tranexamic Acid Timing and Mortality Impact After Trauma. Ann Emerg Med. 2025 Aug 1:S0196-0644(25)00989-8. doi: 10.1016/j.annemergmed.2025.06.609. Epub ahead of print. PMID: 40751727.

https://www.annemergmed.com/article/S0196-0644(25)00989-8/fulltext?rss=yes

BRASH syndrome is more than the sum of its parts. In this episode, we unpack this complex clinical entity defined by bradycardia, renal failure, AV node blocker use, shock, and hyperkalemia...and explore how these factors create a dangerous, self-perpetuating cycle. You’ll learn how to distinguish BRASH from isolated hyperkalemia or AV blocker toxicity, understand the synergistic physiology behind its rapid progression, and discover a multimodal treatment approach that targets every component at once. From volume management to bradycardia support and electrolyte correction, we’ll walk through practical strategies to break the cycle and improve patient outcomes. Whether you’re in emergency medicine, critical care, or just curious about complex pathophysiology, this episode delivers the knowledge you need to act fast and think comprehensively.

In this episode, we explore an innovative approach to managing congestive heart failure (CHF) in the Emergency Department: the use of a patient-directed, weight-based sliding scale furosemide plan. This strategy empowers patients to adjust their diuretic dose based on daily weight changes, aiming to improve self-management, reduce ED visits, and prevent hospital admissions. We also examine the role of a sliding scale furosemide plan in enabling patients to proactively and promptly adjust their dose, helping to address and offset the burden on an overstretched healthcare system, particularly in emergency settings.

What exactly qualifies as insomnia...and how does it differ from the occasional restless night? In this episode, we unpack the clinical definition of insomnia and demystify key sleep science terms like sleep latency, total sleep time, and sleep efficiency. We explore the far-reaching impacts of chronic insomnia on both physical and mental health, before guiding you through evidence-based treatment strategies. Tune in for a comprehensive look at pharmacologic options including Dual Orexin Receptor Antagonists (DORAs), Benzodiazepines, BRAs, melatonin agents, antidepressants, and antihistamines...along with their mechanisms, uses, and side effect profiles. Whether you're a clinician or a curious listener, this episode offers clear, concise insights into managing insomnia safely and effectively.

Patients with hepatic cirrhosis are uniquely at risk for both bleeding and clotting, making anticoagulation decisions complex. In this episode, we explore how cirrhosis alters coagulation, the pros and cons of LMWH, warfarin, and DOACs, and why INR isn’t a reliable guide. We also discuss the challenges of managing anticoagulation around procedures and how to individualize therapy in the face of limited evidence. Whether you're in training or practice, this is a must-listen for navigating one of medicine’s most nuanced dilemmas.

In this episode, we dive into the RSI Trial, a groundbreaking study comparing ketamine and etomidate for rapid sequence intubation in critically ill adults. While the trial found no difference in 28-day mortality between the two drugs, it revealed that ketamine was linked to more episodes of cardiovascular collapse, largely due to increased vasopressor use. We unpack the clinical debate around this finding, exploring whether it reflects true hemodynamic instability or the effects of ketamine’s stronger analgesia. Tune in as we explore what this means for critical care practice and challenge the assumption that ketamine is always the safer choice.

When patients arrive with acute decompensated heart failure, IV antibiotics are often started “just in case.” But what if that precaution is doing more harm than good? In this episode, we break down new research showing that unnecessary IV antibiotics, packed with extra fluid and surprising amounts of sodium, can worsen outcomes, extend hospital stays, and even increase readmissions. We explore why these effects happen, what the data reveals, and how smarter antimicrobial stewardship can protect vulnerable heart-failure patients. Tune in to learn why sometimes less treatment truly means better care!

Dive into the complex world of lithium management as we explore how the drug is processed in the body, how common medications affect its levels, and the risks of chronic exposure. We unpack SILENT syndrome, a serious form of long term neurotoxicity, and challenge conventional wisdom around dialysis for lithium toxicity. Discover why careful monitoring and hydration may be safer than rapid intervention and what the latest research says about protecting the brain.

Renal drug dosing is more complex than most clinicians expect. This episode examines why common creatinine based measures such as creatinine clearance and estimated glomerular filtration rate can be misleading, from the biological limitations of creatinine to the risks of applying the wrong calculation to the wrong medication. These inaccuracies can have real clinical consequences, particularly for drugs that demand precise dosing. We discuss the practical challenges clinicians face, including inconsistent guideline use and the limited availability of dosing recommendations based on estimated glomerular filtration rate. The episode highlights how thoughtful clinical judgment, evidence informed resources, and collaboration with pharmacists can help ensure safer and more reliable dosing when kidney function estimates fall short.

In this episode, we explore the growing debate around the role of beta blockers after myocardial infarction, especially for patients who have a preserved or only mildly reduced ejection fraction. Recent studies have challenged the long standing assumption that all post MI patients benefit equally, suggesting that while beta blockers remain essential for those with reduced heart function, their advantage may be far less clear in patients with normal LVEF. We break down the emerging evidence, the nuanced benefits seen in patients with mildly reduced LVEF (40 to 49%), and how clinicians are beginning to shift toward a more individualized, LVEF guided approach to post MI care.

In this episode, we dive into the evolving strategies for treating Pseudomonas aeruginosa infections with piperacillin-tazobactam (PTZ). Challenging the conventional high-dose approach of 4.5g IV every six hours, recent evidence and Monte Carlo simulations suggest that more isn’t always better. For most strains with MICs ≤8 mg/L, the standard 3.375g IV Q6H is usually sufficient, while higher MIC infections (≥16 mg/L) often require extended infusions to maximize the time the drug remains above the MIC (fT>MIC). We break down why time above MIC...not just total dose, is the key to improving clinical outcomes and how this insight is reshaping how we think about optimal PTZ therapy.

In this episode, we dive into the critical role of drug protein binding in pharmacokinetics and why it matters for patient care. Only the unbound, or free, fraction of a drug is pharmacologically active...available for distribution, metabolism, and elimination. We explore how highly protein-bound drugs, often bound to albumin, act as reservoirs, influencing drug half-life and distribution. Changes in protein binding, due to conditions like hypoalbuminemia or drug-drug interactions, can dramatically alter free drug concentrations, risking treatment failure or toxicity. Through real-world case examples involving valproic acid, furosemide, and ceftriaxone, we reveal how understanding protein binding is essential for safe and effective therapy.

Some Common Highly Protein-Bound Drugs and Their Approximate Binding Percentages:

Anticoagulants:

• Warfarin (~99% bound)

Antiepileptics:

• Phenytoin (~90–95% bound)

• Valproic acid (~90–95% bound)

• Carbamazepine (~75–80% bound)

NSAIDs:

• Naproxen (~99% bound)

• Diclofenac (~99% bound)

• Ibuprofen (~99% bound)

Cardiovascular drugs:

• Verapamil (~95% bound)

• Propafenone (~95% bound)

• Amiodarone (~96% bound)

• Furosemide (~95% bound)

Antibiotics:

• Ceftriaxone (~85–95% bound)

• Erythromycin (~90% bound)

• Clindamycin (~90% bound)

• Sulfonamides (Sulfamethoxazole) (~90–95% bound)

• Ertapenem (~85–95% bound)

Psychotropics / Others:

• Diazepam (~98% bound)

• Tolbutamide (~96% bound)

• Clozapine (~95% bound)

• Fluoxetine (~95% bound)

In this episode, we dive into a critical and controversial aspect of rapid sequence intubation (RSI)...the optimal order of administering rocuronium, a paralytic, and ketamine, a sedative. We explore recent research, including a Monte Carlo analysis that quantifies the risk of anesthetic awareness when rocuronium is given before ketamine, highlighting the chilling possibility of patients being paralyzed yet conscious. We also examine an observational study that suggests giving the paralytic first may modestly reduce apnea time, but with the crucial limitation that patient awareness was not assessed. Through scientific insights and a deeply moving personal account of anesthetic awareness, this episode underscores the urgent need for further research and the high stakes of drug sequencing in critically ill patients.

The fever persists but does that mean treatment is failing? Not necessarily. In this episode we unpack why ongoing fevers do not automatically signal the need to escalate antibiotics. Instead, smart stewardship focuses on the bigger picture including hemodynamic stability, improving organ function, and microbiologic data that reveal the true course of infection. You will learn how to interpret persistent fevers, avoid unnecessary drug toxicity, and make informed decisions that fight antibiotic resistance all without overreacting to the thermometer.

Drug resistant status epilepticus and seizures are some of the highest stakes emergencies in the ED. In this episode, we explore the ketogenic diet as an emerging strategy for patients who continue seizing despite standard therapy. We highlight how quickly seizure control can be achieved, why early initiation in critically ill patients is gaining attention, and how this therapy is starting to influence acute care decision making. Tune in to see how a traditionally outpatient therapy is stepping into the ED and ICU playbook for bedside seizure management.

Status epilepticus is a true neurologic emergency where every minute matters. In this episode, we review modern emergency management strategies, starting with benzodiazepines as first line therapy and examining why traditional second line agents like levetiracetam often fall short in rapidly stopping seizures. We explore growing evidence supporting the early use of ketamine, highlighting its ability to terminate refractory seizures while maintaining hemodynamic stability and often avoiding immediate intubation. The discussion emphasizes the importance of adequate early dosing and decisive escalation to prevent long term neurologic injury. Ultimately, this episode makes the case for faster, more aggressive intervention to achieve seizure control within the critical first thirty minutes.

Rate control has long been the default strategy for atrial fibrillation, reserving rhythm control primarily for symptom management. In this episode, we examine the EAST-AFNET 4 trial and the evidence supporting early rhythm control as a means to reduce stroke and cardiovascular death in patients diagnosed within the past year. We discuss how timely initiation of anti arrhythmic therapy or catheter ablation differs fundamentally from delayed rhythm strategies studied in earlier trials. The episode explores why these findings challenge longstanding practice patterns and how they may redefine standard care for newly diagnosed atrial fibrillation, even in minimally symptomatic patients.

Heart failure looks better on paper but is it really gone? In this episode, we explore the landmark TRED HF trial and why a recovered ejection fraction in dilated cardiomyopathy often represents remission rather than cure. Nearly 40% of patients relapsed within six months of stopping therapy, and that risk rose to 65% over five years, sometimes even after medications were restarted at lower doses. We discuss why cardiac imaging and biomarkers still cannot reliably identify who can safely stop treatment. The message is clear: for most patients, continuing guideline directed medical therapy (GDMT) remains essential to protect the heart and prevent relapse.

In this episode, we explore the potential of ketamine as a neuroprotective therapy for patients recovering from cardiac arrest. Brain injury after arrest often follows a “two-hit” process of ischemia and reperfusion, triggering toxic chemical cascades that damage neurons. As an NMDA receptor antagonist, ketamine may interrupt these pathways and help preserve cognitive function. While animal studies show promise, human clinical trials in this population are still lacking. We also discuss how modern evidence challenges old concerns about ketamine and intracranial pressure, highlighting the need for future research on its role in post-arrest neurological outcomes.

This episode explores the emergence of medetomidine, a powerful veterinary sedative, now appearing in the illicit opioid supply and rapidly replacing xylazine across various regions of the United States and Canada. Clinicians are reporting a severe and unfamiliar withdrawal syndrome marked by extreme hypertension, rapid heart rate, and persistent vomiting, often requiring ICU care and resisting standard treatments. We explore how prolonged sedation complicates naloxone reversals, why standard opioid withdrawal treatments frequently fail, and how targeted alpha-2 agonists like dexmedetomidine are emerging as effective stabilization tools. The discussion highlights the urgent need for expanded toxicology screening and updated emergency and public health protocols as the polysubstance crisis continues to evolve.

When managing atrial fibrillation, clinicians face a pivotal choice...control the heart rate or restore normal rhythm. In this episode, we explore emerging evidence showing that for patients with long standing atrial fibrillation, neither strategy clearly outperforms the other in overall cardiovascular outcomes. However, timing changes everything. For patients diagnosed within the past year, early rhythm control can significantly reduce the risk of stroke and cardiac related death. Join us as we break down why the age of the condition, not just the treatment option, should guide clinical decision making.